Immunocore’s Kimmtrak (tebentafusp) Receives the EC’s Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma
- The approval was based on the P-III (IMCgp100-202) trial to evaluate Kimmtrak vs pembrolizumab, ipilimumab, or dacarbazine in HLA-A*02:01+ adult patients with mUM
- The results showed an OS benefit with m-OS of 22mos., OS in the ITT population (82% pembrolizumab; 13% ipilimumab; 6% dacarbazine), 43% received treatment beyond progression with a median duration was 8wks. & no new safety signals were observed, 21.5% were administered after progression
- The treatment-related adverse reactions were manageable & consistent with the proposed MoA grade 3 CRS in <1%. The therapy has received MAA in all EU member states, Iceland, Liechtenstein & Norway, following completion of related national procedures
Ref: Globe Newswire | Image: Linkedin
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.